Barbara J Amorim1,2,3, Vinay Prabhu1, Sara S Marco4, Debra Gervais1, Willian E Palmer1, Pedram Heidari1,2, Mark Vangel5, Philip J Saylor6, Onofrio A Catalano7,8,9. 1. Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA, 02114, USA. 2. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, USA. 3. Division of Nuclear Medicine, State University of Campinas (UNICAMP), Campinas, Brazil. 4. Division of Nuclear Medicine, Puerta de Hierro University Hospital, Madrid, Spain. 5. Biostatistics Center, Massachusetts General Hospital, Harvard Medical School, Boston, USA. 6. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, USA. 7. Department of Radiology, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, White 270, Boston, MA, 02114, USA. ocatalano@mgh.harvard.edu. 8. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, USA. ocatalano@mgh.harvard.edu. 9. Department of Radiology, University of Naples "Parthenope", Naples, Italy. ocatalano@mgh.harvard.edu.
Abstract
PURPOSE: 18F-Fluciclovine is indicated for evaluation of suspected prostate cancer (PCa) biochemical recurrence. There are few studies investigating fluciclovine with PET/MR and none evaluated osseous metastases. Our aim was to assess the performance of 18F-fluciclovine PET/MR (fluciclovine-PET/MR) for detecting osseous metastases in patients with castration-resistant prostate cancer (CRPC). We also investigated possible correlations between SUVmax and ADCmean. METHODS: We evaluated 8 patients with CRPC metastatic to bones, some before and some after radium therapy, who underwent 13 fluciclovine-PET/MR studies. We analyzed the performance of radionuclide bone scan (RBS), MR alone, fluciclovine-PET alone, and fluciclovine-PET/MR in detecting osseous metastases. Lesion size, characteristics (early sclerotic, late sclerotic, mixed, lytic), SUVmax, and ADCmean were assessed. The reference standard was a combination of clinical information and correlation with both prior and follow-up imaging. RESULTS: Of 347 metastatic bony lesions in 13 studies, 238/347 (68%) were detected by fluciclovine-PET alone, 286/347 (82%) by RBS, 344/347 (99%) by MR alone, and 347/347 (100%) by fluciclovine-PET/MR. Fluciclovine-PET/MR and MR had the best performance (p < 0.001). There was no statistically significant difference between fluciclovine-PET/MR and MR alone (p = 0.25). Fluciclovine-PET had a lower detection rate especially with late sclerotic lesions (p < 0.001). There was a moderate inverse correlation between lesion SUVmax and ADCmean (r = - 0.49; p < 0.001). CONCLUSIONS: This study suggests that fluciclovine-PET/MR and MR have high sensitivity for detecting osseous metastases in CRPC. Fluciclovine-PET alone underperformed in detecting late sclerotic lesions. The inverse correlation between SUVmax and ADCmean suggests a possible relationship between tumor metabolism and cellularity.
PURPOSE:18F-Fluciclovine is indicated for evaluation of suspected prostate cancer (PCa) biochemical recurrence. There are few studies investigating fluciclovine with PET/MR and none evaluated osseous metastases. Our aim was to assess the performance of 18F-fluciclovine PET/MR (fluciclovine-PET/MR) for detecting osseous metastases in patients with castration-resistant prostate cancer (CRPC). We also investigated possible correlations between SUVmax and ADCmean. METHODS: We evaluated 8 patients with CRPC metastatic to bones, some before and some after radium therapy, who underwent 13 fluciclovine-PET/MR studies. We analyzed the performance of radionuclide bone scan (RBS), MR alone, fluciclovine-PET alone, and fluciclovine-PET/MR in detecting osseous metastases. Lesion size, characteristics (early sclerotic, late sclerotic, mixed, lytic), SUVmax, and ADCmean were assessed. The reference standard was a combination of clinical information and correlation with both prior and follow-up imaging. RESULTS: Of 347 metastatic bony lesions in 13 studies, 238/347 (68%) were detected by fluciclovine-PET alone, 286/347 (82%) by RBS, 344/347 (99%) by MR alone, and 347/347 (100%) by fluciclovine-PET/MR. Fluciclovine-PET/MR and MR had the best performance (p < 0.001). There was no statistically significant difference between fluciclovine-PET/MR and MR alone (p = 0.25). Fluciclovine-PET had a lower detection rate especially with late sclerotic lesions (p < 0.001). There was a moderate inverse correlation between lesion SUVmax and ADCmean (r = - 0.49; p < 0.001). CONCLUSIONS: This study suggests that fluciclovine-PET/MR and MR have high sensitivity for detecting osseous metastases in CRPC. Fluciclovine-PET alone underperformed in detecting late sclerotic lesions. The inverse correlation between SUVmax and ADCmean suggests a possible relationship between tumor metabolism and cellularity.
Entities:
Keywords:
Fluciclovine; Osseous metastases; PET/MR; Prostate cancer
Authors: Eva Dyrberg; Helle W Hendel; Tri Hien Viet Huynh; Tobias Wirenfeldt Klausen; Vibeke B Løgager; Claus Madsen; Erik M Pedersen; Maria Pedersen; Henrik S Thomsen Journal: Eur Radiol Date: 2018-08-21 Impact factor: 5.315
Authors: Ivan Jambor; Anna Kuisma; Esa Kähkönen; Jukka Kemppainen; Harri Merisaari; Olli Eskola; Jarmo Teuho; Ileana Montoya Perez; Marko Pesola; Hannu J Aronen; Peter J Boström; Pekka Taimen; Heikki Minn Journal: Eur J Nucl Med Mol Imaging Date: 2017-11-16 Impact factor: 9.236
Authors: David M Schuster; Cristina Nanni; Stefano Fanti; Shuntaro Oka; Hiroyuki Okudaira; Yusuke Inoue; Jens Sörensen; Rikard Owenius; Peter Choyke; Baris Turkbey; Trond V Bogsrud; Tore Bach-Gansmo; Raghuveer K Halkar; Jonathon A Nye; Oluwaseun A Odewole; Bital Savir-Baruch; Mark M Goodman Journal: J Nucl Med Date: 2014-11-13 Impact factor: 10.057
Authors: Mattijs Elschot; Kirsten M Selnæs; Elise Sandsmark; Brage Krüger-Stokke; Øystein Størkersen; Guro F Giskeødegård; May-Britt Tessem; Siver A Moestue; Helena Bertilsson; Tone F Bathen Journal: J Nucl Med Date: 2017-10-06 Impact factor: 10.057
Authors: Jad S Husseini; Bárbara Juarez Amorim; Angel Torrado-Carvajal; Vinay Prabhu; David Groshar; Lale Umutlu; Ken Herrmann; Lina García Cañamaque; José Ramón García Garzón; William E Palmer; Pedram Heidari; Tiffany Ting-Fang Shih; Jacob Sosna; Cristina Matushita; Juliano Cerci; Marcelo Queiroz; Valdair Francisco Muglia; Marcello H Nogueira-Barbosa; Ronald J H Borra; Thomas C Kwee; Andor W J M Glaudemans; Laura Evangelista; Marco Salvatore; Alberto Cuocolo; Andrea Soricelli; Christian Herold; Andrea Laghi; Marius Mayerhoefer; Umar Mahmood; Ciprian Catana; Heike E Daldrup-Link; Bruce Rosen; Onofrio A Catalano Journal: Eur J Nucl Med Mol Imaging Date: 2021-02-22 Impact factor: 9.236